Country Trust Bank Has $36.73 Million Position in IQVIA Holdings Inc. $IQV

Country Trust Bank cut its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 8.4% in the third quarter, Holdings Channel reports. The fund owned 193,381 shares of the medical research company’s stock after selling 17,813 shares during the period. Country Trust Bank’s holdings in IQVIA were worth $36,731,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the company. Alliancebernstein L.P. raised its stake in shares of IQVIA by 0.6% in the second quarter. Alliancebernstein L.P. now owns 3,555,929 shares of the medical research company’s stock valued at $560,379,000 after acquiring an additional 19,573 shares during the last quarter. Artisan Partners Limited Partnership bought a new position in IQVIA in the second quarter valued at approximately $515,772,000. JPMorgan Chase & Co. grew its stake in shares of IQVIA by 22.8% during the second quarter. JPMorgan Chase & Co. now owns 3,126,171 shares of the medical research company’s stock worth $492,659,000 after purchasing an additional 581,157 shares during the period. Nordea Investment Management AB increased its stake in shares of IQVIA by 12.3% in the 3rd quarter. Nordea Investment Management AB now owns 2,314,219 shares of the medical research company’s stock valued at $421,257,000 after acquiring an additional 253,759 shares during the last quarter. Finally, Lazard Asset Management LLC raised its holdings in IQVIA by 6.1% in the second quarter. Lazard Asset Management LLC now owns 1,866,537 shares of the medical research company’s stock worth $294,145,000 after purchasing an additional 107,500 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Wall Street Zen upgraded IQVIA from a “hold” rating to a “buy” rating in a research report on Saturday, December 20th. Mizuho set a $266.00 price target on IQVIA in a research report on Friday, January 9th. Barclays set a $230.00 target price on shares of IQVIA in a research note on Monday, December 15th. TD Cowen downgraded shares of IQVIA from a “buy” rating to a “hold” rating and upped their price objective for the company from $206.00 to $215.00 in a report on Monday, November 3rd. Finally, Baird R W upgraded IQVIA from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 29th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, IQVIA presently has an average rating of “Moderate Buy” and a consensus price target of $249.19.

IQVIA Stock Performance

IQVIA stock opened at $241.38 on Friday. The business’s 50-day moving average price is $226.75 and its two-hundred day moving average price is $202.50. The stock has a market cap of $41.11 billion, a PE ratio of 33.11, a P/E/G ratio of 2.46 and a beta of 1.36. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $247.04. The company has a quick ratio of 0.70, a current ratio of 0.70 and a debt-to-equity ratio of 2.03.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share for the quarter, beating analysts’ consensus estimates of $2.98 by $0.02. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The firm had revenue of $4.10 billion for the quarter, compared to analyst estimates of $4.07 billion. During the same quarter last year, the business posted $2.84 earnings per share. The company’s quarterly revenue was up 5.2% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. As a group, analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other IQVIA news, insider Eric Sherbet sold 4,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total transaction of $878,800.00. Following the sale, the insider directly owned 27,108 shares of the company’s stock, valued at $5,955,627.60. The trade was a 12.86% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 1.60% of the stock is owned by insiders.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.